Browse by author
Lookup NU author(s): Dr Gordon Duncan,
Dr Michael FirbankORCiD,
Professor Alison Yarnall,
Dr Tien Khoo,
Professor John O'Brien,
Professor David Burn
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Introduction: With a cumulative incidence approaching 80%, Parkinson's disease dementia (PDD) is a common complication of Parkinson's disease (PD). Earlier in the disease; subtle cognitive impairments are frequent. In patients with PDD, magnetic resonance imaging (MRI) demonstrates extensive grey matter (GM) loss; however, the temporal course of such change is poorly understood. We aimed to determine whether GM atrophy was present in early PD with mild cognitive impairment (PD-MCI) compared with patients with normal cognition (PD-NC); and if it correlated with neuropsychological testing. Methods: Attention, executive, memory, language and visuospatial functions were assessed and MCI was determined using Movement Disorder Society (MDS) criteria. Patients were considered impaired if they scored 1.5 SD below age-adjusted scores. GM volume differences were evaluated using voxel-based morphometry of GM segments from T1 weighted 3T MRI. Results: A total of 125 patients with early PD and 50 controls participated. The mean age and disease duration of the PD patients was 66 ± 10 years and 6.2 ± 4.7 months, respectively. There were no differences in age, gender or education with controls. PD patients performed more poorly in all cognitive tests. Frequencies of impairments were memory (17.6%), executive (13.6%), attention (10.4%), visuospatial (9.6%) and language (0%). Impaired sematic fluency (SF) correlated with GM loss, there was no association between impairments in other domain-specific tests and GM volume. Of the total, 39.2% of patients were classified as PD-MCI. After correcting for age and intracranial volume, there was no significant difference in GM loss compared with PD-NC or controls. Conclusion: GM atrophy is not prominent in early PD, either in patients with MCI or normal cognition, suggesting that GM loss occurs with disease progression. This neuro-degenerative process may be quantifiable using MRI, and its utility as a biomarker for observational and therapeutic studies warrants further investigation. The association with SF is interesting; impaired SF has been found to predict subsequent PDD.
Author(s): Khoo TK; O'Brien JT; Burn DJ; Firbank MJ; Yarnall AJ; Duncan GW; Barker RA
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: Age and Ageing
Year of Conference: 2013
Publisher: Oxford University Press
Library holdings: Search Newcastle University Library for this item